Arvinas

Arvinas builds more than drugs. It builds the system that decides which drugs should exist in the first place, and that distinction changes how you value every move they make. Founded in 2013 out of Yale science in New Haven, Connecticut, the company traces back to Craig Crews, Ph.D., whose research did not just identify new targets, it redefined what a target could be. Instead of blocking harmful proteins, Arvinas set out to remove them entirely. Not control the signal. Eliminate the source.

That idea became PROTAC, a technology that reads like chemistry but behaves like strategy. These molecules recruit the body’s own disposal system to tag and degrade disease-causing proteins. The implication is simple and dangerous in the best way. If you can degrade what others can only inhibit, the definition of “druggable” starts to expand, and with it, the size of the opportunity. Oncology and other serious diseases stop being a maze of workarounds and start looking more like solvable equations.

Leadership has evolved to meet that moment. Randy Teel, Ph.D. stepped in as President and CEO in February 2026, moving up from CBO with a mandate that is less about discovery and more about delivery. John Houston, Ph.D., who helped scale the company into a clinical-stage force, now remains on the Board, while Briggs Morrison, M.D. chairs it. That combination signals continuity where it matters and urgency where it counts. This is not a reset. It is an acceleration.

Arvinas is now a Nasdaq-listed company operating with the discipline of public markets and the ambition of a platform biotech. Partnerships with leading pharmaceutical players, including Pfizer, are not side quests. They are proof that the platform travels, that the science translates, and that the economics can scale. The pipeline spans multiple serious diseases, anchored in the same core belief that degrading a protein is often more powerful than simply turning it down.

Inside the company, the culture reflects the science. Patient-first is not a slogan when your work determines whether a therapy exists at all. Teams move across chemistry, biology, and clinical development with a shared language built around evidence, not ego. The people who thrive here are the ones who are comfortable operating where the map is still being drawn, where the right answer is not obvious but the stakes are.

The edge is not just the molecules. It is the accumulation of know-how, the repetition of building within a single modality, and the credibility that comes from being early and still standing. In a market that rewards both narrative and numbers, Arvinas has something rarer: a platform that compounds.

They are hiring across research, development, and corporate functions, and if you have been looking for a place where the science actually dictates the strategy, this is one worth studying closely. Follow the story, dig into the pipeline, or step into it yourself. The next chapter is already in motion, and it is not slowing down.